The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor γ Modulator That Promotes Adipogenesis*

The ability of pollutants to affect human health is a major concern, justified by the wide demonstration that reproductive functions are altered by endocrine disrupting chemicals. The definition of endocrine disruption is today extended to broader endocrine regulations, and includes activation of metabolic sensors, such as the peroxisome proliferator-activated receptors (PPARs). Toxicology approaches have demonstrated that phthalate plasticizers can directly influence PPAR activity. What is now missing is a detailed molecular understanding of the fundamental basis of endocrine disrupting chemical interference with PPAR signaling. We thus performed structural and functional analyses that demonstrate how monoethyl-hexyl-phthalate (MEHP) directly activates PPARγ and promotes adipogenesis, albeit to a lower extent than the full agonist rosiglitazone. Importantly, we demonstrate that MEHP induces a selective activation of different PPARγ target genes. Chromatin immunoprecipitation and fluorescence microscopy in living cells reveal that this selective activity correlates with the recruitment of a specific subset of PPARγ coregulators that includes Med1 and PGC-1α, but not p300 and SRC-1. These results highlight some key mechanisms in metabolic disruption but are also instrumental in the context of selective PPAR modulation, a promising field for new therapeutic development based on PPAR modulation.

[1]  Aurélien Grosdidier,et al.  Combined Simulation and Mutagenesis Analyses Reveal the Involvement of Key Residues for Peroxisome Proliferator-activated Receptorα Helix 12 Dynamic Behavior* , 2007, Journal of Biological Chemistry.

[2]  W. Wahli,et al.  Association with Coregulators Is the Major Determinant Governing Peroxisome Proliferator-activated Receptor Mobility in Living Cells* , 2007, Journal of Biological Chemistry.

[3]  G. Mortier,et al.  qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.

[4]  Tetsuo Takahashi,et al.  In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway. , 2006, Toxicology and applied pharmacology.

[5]  Bruce Blumberg,et al.  Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. , 2006, Molecular endocrinology.

[6]  T. Fujimura,et al.  A Selective Peroxisome Proliferator-Activated Receptor γ Modulator with Distinct Fat Cell Regulation Properties , 2006, Journal of Pharmacology and Experimental Therapeutics.

[7]  K. Korach,et al.  Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. , 2006, Endocrinology.

[8]  W. Wahli,et al.  Differentiation of Trophoblast Giant Cells and Their Metabolic Functions Are Dependent on Peroxisome Proliferator-Activated Receptor β/δ , 2006, Molecular and Cellular Biology.

[9]  Armin Ruf,et al.  A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .

[10]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[11]  B. Blumberg,et al.  New modes of action for endocrine-disrupting chemicals. , 2006, Molecular endocrinology.

[12]  B. L. Bálint,et al.  Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. , 2006, Endocrine, metabolic & immune disorders drug targets.

[13]  Ivan Rusyn,et al.  Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver , 2006, Critical reviews in toxicology.

[14]  Michael Lehrke,et al.  The Many Faces of PPARγ , 2005, Cell.

[15]  R. Waring,et al.  Endocrine disrupters: A human risk? , 2005, Molecular and Cellular Endocrinology.

[16]  U. Kintscher,et al.  Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. , 2005, Diabetes.

[17]  Daniel Sage,et al.  PixFRET, an ImageJ plug‐in for FRET calculation that can accommodate variations in spectral bleed‐throughs , 2005, Microscopy research and technique.

[18]  M. Lazar,et al.  PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1 , 2005 .

[19]  Y. Chao,et al.  Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity , 2005 .

[20]  W. Wahli,et al.  Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*♦ , 2005, Journal of Biological Chemistry.

[21]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[22]  M. Brady,et al.  The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor γ Transcriptional Activity and Repress 3T3-L1 Adipogenesis* , 2005, Journal of Biological Chemistry.

[23]  T. Nakanishi,et al.  Organotin Compounds Promote Adipocyte Differentiation as Agonists of the Peroxisome Proliferator-Activated Receptor γ/Retinoid X Receptor Pathway , 2005, Molecular Pharmacology.

[24]  M. Lazar,et al.  Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. , 2005, Genes & development.

[25]  J. Corton,et al.  Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. , 2005, Toxicology.

[26]  T. Fujimura,et al.  FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. , 2005, Journal of pharmacological sciences.

[27]  D. Lai,et al.  Rodent Carcinogenicity of Peroxisome Proliferators and Issues on Human Relevance , 2004, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[28]  J. V. Vanden Heuvel,et al.  Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  I. Kawamura,et al.  Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. , 2004, European journal of pharmacology.

[30]  W. Wahli,et al.  Be fit or be sick: peroxisome proliferator-activated receptors are down the road. , 2004, Molecular endocrinology.

[31]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[32]  Heike Brand,et al.  Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter , 2003, Cell.

[33]  Terry Speed,et al.  Normalization of cDNA microarray data. , 2003, Methods.

[34]  D. Waxman,et al.  Activation of PPARα and PPARγ by Environmental Phthalate Monoesters , 2003 .

[35]  Charles L. Brooks,et al.  New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..

[36]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[37]  Carlos Sonnenschein,et al.  Endocrine disruptors: from Wingspread to environmental developmental biology , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[38]  B. Spiegelman,et al.  Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis , 2002, Nature.

[39]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[40]  J. Auwerx,et al.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.

[41]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[42]  P E Bourne,et al.  The Protein Data Bank. , 2002, Nucleic acids research.

[43]  David J. Waxman,et al.  trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals , 1999 .

[44]  J. Auwerx,et al.  p300 Interacts with the N- and C-terminal Part of PPARγ2 in a Ligand-independent and -dependent Manner, Respectively* , 1999, The Journal of Biological Chemistry.

[45]  D. Robyr,et al.  Transcriptional Regulatory Patterns of the Myelin Basic Protein and Malic Enzyme Genes by the Thyroid Hormone Receptors α1 and β1* , 1998, The Journal of Biological Chemistry.

[46]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[47]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[48]  R. Schulte‐Hermann,et al.  Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. , 1996, Critical reviews in toxicology.

[49]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[50]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[51]  D. T. Williams,et al.  Retention, excretion and metabolism of Di-(2-ethylhexyl) phthalate administered orally to the rat , 1974, Bulletin of environmental contamination and toxicology.